Abstract
Introduction
Head and neck cancer (HNC), like many other forms of cancer, is usually detected in advanced stages, causing poor survival outcomes. Lack of specific and sensitive screening markers for early detection of HNC has worsened the scenario for the patients as well as the clinicians. Therefore, identification of efficient, noninvasive and affordable screening marker/methodology with high specificity and sensitivity is imminent need of situation.
Objectives
This study aims to identify and characterize urinary volatomic alterations specific to HNC.
Methods
Volatomic analysis of urine samples collected from HNC patients (n = 29) and healthy controls (n = 31) was performed using headspace solid phase microextraction coupled to gas chromatography mass spectrometry (GC–MS). Both univariate and multivariate statistical approaches were used to investigate HNC specific volatomic alterations.
Results
Statistical analysis revealed a total of 28 metabolites with highest contribution towards discrimination of HNC patients from healthy controls (VIP >1, p < 0.05, Log2 FC ≥0.58/≤−0.57). The discrimination efficiency and accuracy of urinary VOCs was ascertained by ROC curve analysis that allowed the identification of four metabolites viz. 2,6-dimethyl-7-octen-2-ol, 1-butanol, p-xylene and 4-methyl-2-heptanone with highest sensitivity and specificity to discriminate HNC patients from healthy controls. Further, the metabolic pathway analysis identified several dysregulated pathways in HNC patients and their detailed investigations could unravel novel mechanistic insights into the disease pathophysiology.
Conclusion
Overall, this study provides valuable fingerprint of the volatile profile of HNC patients, which in turn, might help in improving the current understanding of this form of cancer and lead to the development of non-invasive approaches for HNC diagnosis.
Similar content being viewed by others
References
Amann, A., Costello, B. D. L., Miekisch, W., Schubert, J., Buszewski, B., Pleil, J., et al. (2014). The human volatilome: Volatile organic compounds (VOCs) in exhaled breath, skin emanations, urine, feces and saliva. Journal of Breath Research, 8(3), 34001.
Arasaradnam, R. P., McFarlane, M. J., Ryan-Fisher, C., Westenbrink, E., Hodges, P., Thomas, M. G., et al. (2014). Detection of colorectal cancer (CRC) by urinary volatile organic compound analysis. PloS ONE, 9(9), e108750.
Barrera, G. (2012). Oxidative stress and lipid peroxidation products in cancer progression and therapy. ISRN Oncology, 2012(137289), 21.
Boccard, J., & Rudaz, S. (2013). Mass Spectrometry Metabolomic Data Handling for Biomarker Discovery. In H. J. Issaq & T. D. Veenstra (Eds.), Proteomic and metabolomic approaches to biomarker discovery (pp. 425–445). Boston: Academic Press.
Brand, A., Leibfritz, D., Hamprecht, B., & Dringen, R. (1998). Metabolism of cysteine in astroglial cells: Synthesis of hypotaurine and taurine. Journal of Neurochemistry, 71(2), 827–832.
Broadhurst, D. I., & &Kell, D. B. (2006).Statistical strategies for avoiding false discoveries in metabolomics and related experiments. Metabolomics, 2(4), 171–196.
Burke, D. G., Halpern, B., Malegan, D., McCairns, E., Danks, D., Schlesinger, P., & Wilken, B. (1983). Profiles of urinary volatiles from metabolic disorders characterized by unusual odors. Clinical Chemistry, 29(10), 1834–1838.
Chen, J. L., Tang, H. Q., Hu, J. D., Fan, J., Hong, J., & Gu, J. Z. (2010). Metabolomics of gastric cancer metastasis detected by gas chromatography and mass spectrometry. World Journal of Gastroenterology: WJG, 16(46), 5874–5880.
Cummings, J. H. (1981). Short chain fatty acids in the human colon. Gut, 22(9), 763–779.
Downes, M. R., Byrne, J. C., Pennington, S. R., Dunn, M. J., Fitzpatrick, J. M., & Watson, R. W. G. (2007). Urinary markers for prostate cancer. BJU International, 99(2), 263–268.
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., et al. (2014). Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer, 136(5), E359–E386
Fiehn, O., Robertson, D., Griffin, J. L., Van der Werf, M., Nikolau, B., Morrison, N., et al. (2007). The metabolomics standard initiative (MSI). Metabolomics, 3(3), 175–178.
Frank Kneepkens, C. M., Lepage, G., & Roy, C. C. (1994). The potential of the hydrocarbon breath test as a measure of lipid peroxidation. Free Radical Biology and Medicine, 17(2), 127–160.
Gossai, D., & Lau-Cam, C. A. (2009). The effects of taurine, hypotaurine, and taurine homologs on erythrocyte morphology, membrane fluidity and cytoskeletal spectrin alterations due to diabetes, alcoholism and diabetes-alcoholism in the rat. Advances in Experimental Medicine and Biology, 643, 369–379.
Griffin, J. L., Nicholls, A. W., Daykin, C. A., Heald, S., Keun, H. C., Schuppe-Koistinen, I., et al. (2007). Standard reporting requirements for biological samples in metabolomics experiments: Mammalian/in vivo experiments. Metabolomics, 3(3), 179–188.
Guengerich, F. P., Kim, D. H., & Iwasaki, M. (1991). Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chemical Research in Toxicology, 4(2), 168–179.
Guo, L., Wang, C., Chi, C., Wang, X., Liu, S., Zhao, W., et al. (2015). Exhaled breath volatile biomarker analysis for thyroid cancer. Translational Research, 166(2), 188–195.
Haick, H., Broza, Y. Y., Mochalski, P., Ruzsanyi, V., & Amann, A. (2014). Assessment, origin, and implementation of breath volatile cancer markers. Chemical Society Reviews, 43(5), 1423–1449.
Hakim, M., Broza, Y. Y., Barash, O., Peled, N., Phillips, M., Amann, A., & Haick, H. (2012). Volatile organic compounds of lung cancer and possible biochemical pathways. Chemical Reviews, 112(11), 5949–5966.
Halliwell, B., Gutteridge, J. M., & Cross, C. E. (1992). Free radicals, antioxidants, and human disease: Where are we now? The Journal of Laboratory and Clinical Medicine, 119(6), 598–620.
Huang, S., Chong, N., Lewis, N. E., Jia, W., Xie, G., & Garmire, L. X. (2016). Novel personalized pathway-based metabolomics models reveal key metabolic pathways for breast cancer diagnosis. Genome Medicine, 8(1), 34.
Inal, E., Lacin, M., Asal, K., Ceylan, A., Koybasioglu, A., Ileri, F., & Uslu, S. S. (2004). The significance of ferritin, lipid-associated sialic acid, CEA, squamous cell carcinoma (SCC) antigen, and CYFRA 21 – 1 levels in SCC of the head and neck. Kulak Burun Bogaz Ihtis Derg, 12(1–2), 23–30.
Liu, H., Wang, H., Li, C., Wang, L., Pan, Z., & Wang, L. (2013). Investigation of volatile organic metabolites in lung cancer pleural effusions by solid-phase microextraction and gas chromatography/mass spectrometry. Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences, 945–946, 53–59.
Lunt, S. Y., & Vander Heiden, M. G. (2011). Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation. Annual Review of Cell and Developmental Biology, 27, 441–464.
Mallath, M. K., Taylor, D. G., Badwe, R. A., Rath, G. K., Shanta, V., Pramesh, C. S., et al. (2014). The growing burden of cancer in India: Epidemiology and social context. The Lancet Oncology, 15(6), e205–e212.
Martinez-Outschoorn, U. E., Lin, Z., Whitaker-Menezes, D., Howell, A., Lisanti, M. P., & Sotgia, F. (2012). Ketone bodies and two-compartment tumor metabolism: Stromal ketone production fuels mitochondrial biogenesis in epithelial cancer cells. Cell Cycle, 11(21), 3956–3963.
Mishra, A., & Meherotra, R. (2014). Head and neck cancer: Global burden and regional trends in India. Asian Pacific Journal of Cancer Prevention, 15(2), 537–550.
Obuchowski, N. A., Blackmore, C. C., Karlik, S., & Reinhold, C. (2005). Fundamentals of clinical research for radiologists. American Journal of Roentgenology, 184(2), 364–372.
Panieri, E., & Santoro, M. (2016). ROS homeostasis and metabolism: A dangerous liason in cancer cells. Cell Death and Disease, 7(6), e2253.
Phillips, M., Gleeson, K., Hughes, J. M. B., Greenberg, J., Cataneo, R. N., Baker, L., & McVay, W. P. (1999). Volatile organic compounds in breath as markers of lung cancer: A cross-sectional study. Lancet, 353(9168), 1930–1933.
Potter, M., Newport, E., & Morten, K. J. (2016). The Warburg effect: 80 years on. Biochemical Society Transactions, 44(5), 1499–1505.
Pradhan, M. P., Desai, A., & Palakal, M. J. (2013).Systems biology approach to stage-wise characterization of epigenetic genes in lung adenocarcinoma. BMC Systems Biology, 7, 141.
Rezende, T. M. B., Freire, M. d. S., & Franco, O. L. (2010). Head and neck cancer. Cancer, 116(21), 4914–4925.
Roberts, M. J., Schirra, H. J., Lavin, M. F., & Gardiner, R. A. (2011). Metabolomics: A novel approach to early and noninvasive prostate cancer detection. Korean Journal of Urology, 52(2), 79–89.
Roy, D., Mondal, S., Wang, C., He, X., Khurana, A., Giri, S., et al. (2014). Loss of HSulf-1 promotes altered lipid metabolism in ovarian cancer. Cancer & Metabolism, 2, 13.
Schug, Z. T., Voorde, J., Vande, & Gottlieb, E. (2016). The metabolic fate of acetate in cancer. Nature Reviews Cancer, 16(11), 708–717.
Shen, C., Sun, Z., Chen, D., Su, X., Jiang, J., Li, G., et al. (2015). Developing urinary metabolomic signatures as early bladder cancer diagnostic markers. Omics: A Journal of Integrative Biology, 19(1), 1–11.
Silva, C. L., Passos, M., & &Câmara, J. S. (2011). Investigation of urinary volatile organic metabolites as potential cancer biomarkers by solid-phase microextraction in combination with gas chromatography-mass spectrometry. British Journal of Cancer, 105(12), 1894–1904.
Silva, C. L., Passos, M., & &Câmara, J. S. (2012). Solid phase microextraction, mass spectrometry and metabolomic approaches for detection of potential urinary cancer biomarkers - A powerful strategy for breast cancer diagnosis. Talanta, 89, 360–368.
Sponring, A., Filipiak, W., Mikoviny, T., Ager, C., Schubert, J., Miekisch, W., et al. (2009). Release of volatile organic compounds from the lung cancer cell line NCI-H2087 in vitro. Anticancer Research, 29(1), 419–426.
Stewart, B. W., & Wild, C. P. (2014). World Cancer Report 2014. Geneva: World Health Organization.
Tamás, L., Szentkúti, G., Eros, M., Dános, K., Brauswetter, D., Szende, B., et al. (2011). Differential biomarker expression in head and neck cancer correlates with anatomical localization. Pathology and Oncology Research, 17(3), 721–727.
Tiruppathi, C., Brandsch, M., Miyamoto, Y., Ganapathy, V., & Leibach, F. H. (1992). Constitutive expression of the taurine transporter in a human colon carcinoma cell line. American Journal of Physiology, 263(5), G625–G631.
Ulanowska, A., Ligor, T., Michel, M., & Buszewski, B. (2010). Hyphenated and unconventional methods for searching volatile cancer biomarkers. Ecological Chemistry and Engineering S-Chemia I InzynieriaEkologiczna S. 17, 9–23
Warburg, O. (1956). On the origin of cancer cells. Science, 123(3191), 309–314.
Warburg, O., Ding, Y., Sharma, J., Paetz, M. B., Meixensberger, J., Gaunitz, F., et al. (1927). The metabolism of tumors in the body. The Journal of General Physiology, 8(6), 519–530.
Wilson, A. D. (2015). Advances in electronic-nose technologies for the detection of volatile biomarker metabolites in the human breath. Metabolites, 5(1), 140–163.
Wyss, A., Hashibe, M., Chuang, S. C., Lee, Y. C. A., Zhang, Z. F., Yu, G. P., et al. (2013). Cigarette, cigar, and pipe smoking and the risk of head and neck cancers: Pooled analysis in the international head and neck cancer epidemiology consortium. American Journal of Epidemiology, 178(5), 679–690.
Xia, J., Sinelnikov, I. V., Han, B., & Wishart, D. S. (2015). MetaboAnalyst 3.0-making metabolomics more meaningful. Nucleic Acids Research, 43(W1), W251–W257.
Xia, J., & Wishart, D. S. (2011). Web-based inference of biological patterns, functions and pathways from metabolomic data using MetaboAnalyst. Nature Protocols, 6(6), 743–760.
Xia, J., Wishart, D. S., & Valencia, A. (2011). MetPA: A web-based metabolomics tool for pathway analysis and visualization. Bioinformatics, 27, 2342–2344.
Yonezawa, K., Nishiumii, S., Kitamoto-Matsuda, J., Fujita, T., Morimoto, K., Yamashita, D., et al. (2013). Serum and tissue metabolomics of head and neck cancer. Cancer Genomics & Proteomics, 10, 233–238.
Acknowledgements
This research was supported by NEW INDIGO HCV project and Department of Biotechnology Grant No. BT/IN/NEW INDIGO/03/RS/2013. The authors are grateful to all the volunteers who participated in the study. RT, KT and RD acknowledges Department of Biotechnology, New Delhi and NEW INDIGO HCV project for research fellowship. The authors also acknowledge FCT—Fundação para a Ciência e Tecnologia (project PEst-UID/QUI/UI0674/2013, CQM, Portuguese Government funds) and ARDITI—Agência Regional para o Desenvolvimento da Investigação Tecnologia e Inovação (projects M1420-01- 0145-FEDER- 000005—Centro de Química da Madeira—CQM+ (Madeira 14–20), and M1420–09-5369- FSE-000001) for the financial support and the Post-Doctoral fellowship granted to Jorge A. M. Pereira.
Author information
Authors and Affiliations
Contributions
Conceived the study: JSC, HAN, SR; Designed the study: RT, KT, JSC, HAN, SR; Performed the experiments: RT, KT; Compiled and analyzed data: RT, KT, JAMP, RD, SR; Statistical analysis: RT, KT, RD, HAN, SR; Drafted the manuscript: RT, KT, JAMP, RD, NK, DS, JSC, HAN, SR; Provided clinical samples: NK, DS; Provided chemicals and reagents: SR.
Corresponding author
Ethics declarations
Conflict of interest
Authors declare no conflict of interest.
Ethical approval
The study was approved by ethics committee of National Centre for Cell Science and Armed Forces Medical College, Pune, India.
Informed consent
Prior informed consent was obtained from all the participants in the study with institutional review approval.
Research involving human participants and/or animals
All protocols and procedures were adhered to institutional ethical standards and/or research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Taware, R., Taunk, K., Pereira, J.A.M. et al. Investigation of urinary volatomic alterations in head and neck cancer: a non-invasive approach towards diagnosis and prognosis. Metabolomics 13, 111 (2017). https://doi.org/10.1007/s11306-017-1251-6
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s11306-017-1251-6